
Astellas Pharma’s logo is pictured at its headquarters in Tokyo, Japan, December 3, 2019.
12:08 JST, May 1, 2023
Tokyo (Jiji Press)—Japanese drugmaker Astellas Pharma Inc. said Monday that it has agreed to buy U.S. biopharmaceutical startup Iveric Bio Inc. for $5.9 billion in its largest corporate acquisition.
Astellas aims to complete the acquisition of Iveric, which develops ophthalmologic drugs, in July-September following U.S. antitrust and other regulatory screenings.
Astellas will take out bank loans and issue commercial paper to finance the acquisition.
Iveric, listed on the U.S. Nasdaq market, has applied for U.S. Food and Drug Administration approval for an age-related macular degeneration drug that is expected to help maintain or restore vision. The screening is expected to finish in August.
"Business" POPULAR ARTICLE
-
Core Inflation in Japan’s Capital Sharply Accelerates in April
-
Rice Prices Rise for 15th Straight Week, with Releases of Stockpiled Rice Slow to Circulate
-
U.S. Holds Fire Over Yen Exchange Rate Targets; Bessent Said to Understand Negative Impact on Markets
-
Japan Must Take Lead in Maintaining Free Trade System, Says Chairman of Japan Trade Group
-
Groundbreaking Ceremony Held for Japan’s 1st Casino Resort; Site Set to Open in Fall of 2030
JN ACCESS RANKING